Value of mucosal assessment and biomarkers in inflammatory bowel disease

References

• Caprilli R, Gassull MA, Escher JC et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut55(Suppl. 1), i36–i58 (2006).
   PubMed Web of Science ®Google Scholar
• Wexner SD, Rosen L, Lowry A et al. Practice parameters for the treatment of mucosal ulcerative colitis – supporting documentation. The Standards Practice Task Force. The American Society of Colon and Rectal Surgeons. Dis. Colon Rectum40(11), 1277–1285 (1997).
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Weber LR, Knox JF et al. Permanent work disability in Crohn’s disease. Am. J. Gastroenterol.103(1), 154–161 (2008).
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Porter CQ et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology135(6), 1907–1913 (2008).
   PubMed Web of Science ®Google Scholar
• Casellas F, Rodrigo L, Nino P, Pantiga C, Riestra S, Malagelada JR. Sustained improvement of health-related quality of life in Crohn’s disease patients treated with infliximab and azathioprine for 4 years. Inflamm. Bowel Dis.13(11), 1395–1400 (2007).
   PubMed Web of Science ®Google Scholar
• Bouhnik Y, Lemann M, Mary JY et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet347(8996), 215–219 (1996).
   PubMed Web of Science ®Google Scholar
• Solberg IC, Vatn MH, Hoie O et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin. Gastroenterol. Hepatol.5(12), 1430–1438 (2007).
   PubMed Web of Science ®Google Scholar
• Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm. Bowel Dis.8(4), 244–250 (2002).
   PubMed Web of Science ®Google Scholar
• Caspersen S, Elkjaer M, Riis L et al. Infliximab for inflammatory bowel disease in Denmark 1999–2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin. Gastroenterol. Hepatol.6(11), 1212–1217; quiz 1176 (2008).
   PubMed Web of Science ®Google Scholar
• Lees CW, Ali AI, Thompson AI et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment. Pharmacol. Ther.29(3), 286–297 (2009).
   PubMed Web of Science ®Google Scholar
• Seiderer J, Zech CJ, Diebold J et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur. J. Gastroenterol. Hepatol.18(5), 553–555 (2006).
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology134(4), 929–936 (2008).
   PubMed Web of Science ®Google Scholar
• Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am. J. Gastroenterol.97(4), 947–953 (2002).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology99(4), 956–963 (1990).
   PubMed Web of Science ®Google Scholar
• Reinisch W, Rutgeerts PJ, Panaccione R et al. Prediction of long-term clinical remission for adalimumab-treated patients with Crohn’s disease by identification of approriate dichotomizing points for SES-CD. Presented at: Digestive Disease Week 2010, American Gastroenterological Association. New Orleans, LA, USA, 1–5 May, 2010 (Abstract 41a).
   Google Scholar
• Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology133(2), 412–422 (2007).
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology138(2), 463–468 (2010).
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm. Bowel Dis.15(9), 1295–1301 (2009).
   PubMed Web of Science ®Google Scholar
• Andersen K, Vogt C, Blondin D et al. Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy. Eur. J. Radiol.58(1), 140–146 (2006).
   PubMed Web of Science ®Google Scholar
• Ergen FB, Akata D, Hayran M et al. Magnetic resonance colonography for the evaluation of colonic inflammatory bowel disease: correlation with conventional colonoscopy. J. Comput. Assist. Tomogr.32(6), 848–854 (2008).
   PubMed Web of Science ®Google Scholar
• Koilakou S, Sailer J, Peloschek P et al. Endoscopy and MR enteroclysis: Equivalent tools in predicting clinical recurrence in patients with Crohn’s disease after ileocolic resection. Inflamm. Bowel Dis.16(2), 198–203 (2009).
   Web of Science ®Google Scholar
• Bozkurt T, Richter F, Lux G. Ultrasonography as a primary diagnostic tool in patients with inflammatory disease and tumors of the small intestine and large bowel. J. Clin. Ultrasound22(2), 85–91 (1994).
   PubMed Web of Science ®Google Scholar
• Fraquelli M, Colli A, Casazza G et al. Role of US in detection of Crohn disease: meta-analysis. Radiology236(1), 95–101 (2005).
   PubMed Web of Science ®Google Scholar
• Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut58(6), 859–868 (2009).
   PubMed Web of Science ®Google Scholar
• Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am. J. Gastroenterol.91(5), 927–934 (1996).
   PubMed Web of Science ®Google Scholar
• Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand. J. Gastroenterol.34(1), 50–54 (1999).
   PubMed Web of Science ®Google Scholar
• Costa F, Mumolo MG, Bellini M et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver Dis.35(9), 642–647 (2003).
   PubMedGoogle Scholar
• Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig. Liver Dis.41(1), 56–66 (2009).
   PubMedGoogle Scholar
• Hanai H, Takeuchi K, Iida T et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig. Dis. Sci.49(9), 1438–1443 (2004).
   PubMed Web of Science ®Google Scholar
• Jones J, Loftus EV Jr, Panaccione R et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin. Gastroenterol. Hepatol.6(11), 1218–1224 (2008).
   PubMed Web of Science ®Google Scholar
• Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand. J. Gastroenterol.39(10), 1017–1020 (2004).
   PubMed Web of Science ®Google Scholar
• Sipponen T, Savilahti E, Karkkainen P et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-α therapy for Crohn's disease. Inflamm. Bowel Dis.14(10), 1392–1398 (2008).
   PubMed Web of Science ®Google Scholar
• Ho GT, Lee HM, Brydon G et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am. J. Gastroenterol.104(3), 673–678 (2009).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Bermejo F, Perez-Calle JL et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm. Bowel Dis.15(8), 1190–1198 (2009).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm. Bowel Dis.15(11), 1746–1754 (2009).
   PubMed Web of Science ®Google Scholar
• D’Inca R, Dal Pont E, Di Leo V et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am. J. Gastroenterol.103(8), 2007–2014 (2008).
   PubMed Web of Science ®Google Scholar
• Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn’s disease. Clin. Gastroenterol. Hepatol. DOI: 10.1016/j.cgh.2010.01.016 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand. J. Gastroenterol.41(6), 720–725 (2006).
   PubMed Web of Science ®Google Scholar
• Darlington GJ, Wilson DR, Lachman LB. Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J. Cell Biol.103(3), 787–793 (1986).
   PubMed Web of Science ®Google Scholar
• Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am. J. Gastroenterol.103(1), 162–169 (2008).
   PubMed Web of Science ®Google Scholar
• Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn’s disease. Dig. Dis. Sci.52(9), 2063–2068 (2007).
   PubMed Web of Science ®Google Scholar
• Brull DJ, Serrano N, Zito F et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler. Thromb. Vasc. Biol.23(11), 2063–2069 (2003).
   PubMed Web of Science ®Google Scholar
• Haukim N, Bidwell JL, Smith AJ et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun.3(6), 313–330 (2002).
   PubMed Web of Science ®Google Scholar
• Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm. Bowel Dis.11(8), 707–712 (2005).
   PubMed Web of Science ®Google Scholar
• Denis MA, Reenaers C, Fontaine F, Belaiche J, Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-reactive protein serum level. Inflamm. Bowel Dis.13(9), 1100–1105 (2007).
   PubMed Web of Science ®Google Scholar
• Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn’s disease. Results of a prospective longitudinal study. J. Clin. Gastroenterol.10(4), 401–405 (1988).
   PubMed Web of Science ®Google Scholar
• Consigny Y, Modigliani R, Colombel JF, Dupas JL, Lemann M, Mary JY. A simple biological score for predicting low risk of short-term relapse in Crohn’s disease. Inflamm. Bowel Dis.12(7), 551–557 (2006).
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut58(4), 492–500 (2009).
   PubMed Web of Science ®Google Scholar
• Papadakis KA, Yang H, Ippoliti A et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn’s disease associations. Inflamm. Bowel Dis.13(5), 524–530 (2007).
   PubMed Web of Science ®Google Scholar
• Papp M, Altorjay I, Norman GL et al. Seroreactivity to microbial components in Crohn’s disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm. Bowel Dis.13(8), 984–992 (2007).
   PubMed Web of Science ®Google Scholar
• Spivak J, Landers CJ, Vasiliauskas EA et al. Antibodies to I2 predict clinical response to fecal diversion in Crohn’s disease. Inflamm. Bowel Dis.12(12), 1122–1130 (2006).
   PubMed Web of Science ®Google Scholar
• Sakiyama T, Fujita H, Tsubouchi H. Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn’s disease. Inflamm. Bowel Dis.14(3), 310–317 (2008).
   PubMed Web of Science ®Google Scholar
• Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am. J. Gastroenterol.102(9), 2058–2069 (2007).
   PubMed Web of Science ®Google Scholar
• Kaser A, Tilg H. Novel therapeutic targets in the treatment of IBD. Expert Opin. Ther. Targets12(5), 553–563 (2008).
   PubMed Web of Science ®Google Scholar
• Kmiec Z. Cytokines in inflammatory bowel disease. Arch. Immunol. Ther. Exp. (Warsz.)46(3), 143–155 (1998).
   PubMedGoogle Scholar